Passage Bio chips away at workforce, prioritizes R&D with UPenn’s James Wilsonnews2022-03-15T14:09:40+00:00March 15th, 2022|FierceBiotech|
AbbVie, eyeing shift to endemic, adds to COVID-19 work with Scripps partnershipnews2022-03-15T13:54:01+00:00March 15th, 2022|FierceBiotech|
Pfizer cancer vaccine science chief poached by Gilead-backed Shoreline Biosciencesnews2022-03-15T12:59:02+00:00March 15th, 2022|FierceBiotech|
Astellas’ menopause drug suffers rare setback as failed Asian trial blots previously pristine recordnews2022-03-15T11:43:42+00:00March 15th, 2022|FierceBiotech|
AnaptysBio’s ACORN fails to grow mighty oak, marking end of development of imsidolimab in acnenews2022-03-15T10:41:42+00:00March 15th, 2022|FierceBiotech|
Moderna hits the gas as it begins dosing of 2nd HIV vaccinenews2022-03-14T19:02:19+00:00March 14th, 2022|FierceBiotech|
‘Biotech sisterhood’: 25 female CEOs find new ways to ‘sponsor’ the next generation at Arizona retreatnews2022-03-14T16:27:28+00:00March 14th, 2022|FierceBiotech|
CAMP4 poaches Translate Bio medical chief, adds ex-Biogen R&D leader Al Sandrock to advisory boardnews2022-03-14T15:22:34+00:00March 14th, 2022|FierceBiotech|
Ascendis scores in phase 3 trial as it looks to expand endocrine-focused portfolionews2022-03-14T13:44:19+00:00March 14th, 2022|FierceBiotech|
BMS-Nektar’s Opdivo combo fails phase 3 in upset to once-largest licensing deal in biotech historynews2022-03-14T12:18:32+00:00March 14th, 2022|FierceBiotech|
